GBT to Host Investor Conference Call on Friday, June 10 and Participate in Upcoming Investor Conferences
June 01 2022 - 4:05PM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced that it will host a conference call and webcast for the
investment community on Friday, June 10, 2022, at 3:00 p.m. CEST
(9:00 a.m. ET) to discuss data on its sickle cell programs
presented at the European Hematology Association (EHA) Annual
Congress and to provide business and R&D updates. To
participate in the conference call, please dial (877) 407-3982
(domestic) or +1 (201) 493-6780 (international). A live webcast
including presentation slides can be accessed on GBT’s website at
www.gbt.com in the Investors section. The archived webcast will be
available for three months following the event.
In addition, GBT will participate at the following investor
conferences:
- William Blair 42nd Annual Growth Stock Conference in Chicago,
IL. GBT will present on Wednesday, June 8, at 10:40 a.m. CT;
and
- Goldman Sachs 43rd Annual Global Healthcare Conference in
Rancho Palos Verdes, CA. GBT will participate in a fireside chat on
Wednesday, June 15, at 8:40 a.m. PT.
The presentation and fireside chat will each be webcast live
from GBT’s website at www.gbt.com in the Investors section. Replays
of the webcasts will be archived and available for one month
following each event.
About Global Blood Therapeutics Global Blood
Therapeutics (GBT) is a biopharmaceutical company dedicated to the
discovery, development and delivery of life-changing treatments
that provide hope to underserved patient communities, starting with
sickle cell disease (SCD). Founded in 2011, GBT is delivering on
its goal to transform the treatment and care of SCD, a lifelong,
devastating inherited blood disorder. The company has introduced
Oxbryta® (voxelotor), the first FDA-approved medicine that directly
inhibits sickle hemoglobin (HbS) polymerization, the root cause of
red blood cell sickling in SCD. GBT is also advancing its pipeline
program in SCD with inclacumab, a P-selectin inhibitor in Phase 3
development to address pain crises associated with the disease, and
GBT021601 (GBT601), the company’s next generation HbS
polymerization inhibitor. In addition, GBT’s drug discovery teams
are working on new targets to develop the next generation of
treatments for SCD. To learn more, please visit www.gbt.com and
follow the company on Twitter @GBT_news.
Contact:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Courtney
Roberts (investors)650-351-7881croberts@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2023 to Apr 2024